Evercore ISI lowered the firm’s price target on Cencora to $250 from $270 and keeps an Outperform rating on the shares. The firm is adjusting estimates and making additions to Evercore’s “Tactical Outperform” and “Tactical Underperform” lists ahead of Q3 earnings from the Healthcare Technology and Distribution group.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COR:
Questions or Comments about the article? Write to editor@tipranks.com